KBP-5074 clinical trials
Also written KBP-5074.
How each study uses KBP-5074 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
Studies by the year they started
9 studies that test it; most in 2020 (3)
| Year | Studies |
|---|---|
| 2014 | 1 |
| 2015 | 1 |
| 2016 | 1 |
| 2017 | 1 |
| 2018 | 1 |
| 2020 | 3 |
| 2021 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 9 · Other 0
KBP Biosciences (8) · Novo Nordisk A/S (1)
Studies
Open first, then newest update. How each study uses KBP-5074 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 9
- Efficacy and Safety of KBP-5074 in Uncontrolled Hypertension and Moderate or Severe Chronic Kidney Disease (CKD)TerminatedPhase 3Novo Nordisk A/SNCT04968184Written as KBP-5074How we know
- Phase 2b Study of KBP-5074 in Subjects With Uncontrolled Hypertension and Advanced Chronic Kidney DiseaseCompletedPhase 2KBP BiosciencesNCT03574363Written as KBP-5074 0.25 mg tabletHow we know
- Safety, Tolerability, and Pharmacokinetics of KBP-5074 Following Oral Administration in Chronic Kidney DiseaseCompletedPhase 1KBP BiosciencesNCT02837237Written as KBP-5074How we know
- Mass Balance Study of KBP-5074 in Healthy Male SubjectsCompletedPhase 1KBP BiosciencesNCT04634812Written as KBP-5074How we know
- Safety, Tolerability and Pharmacokinetics of KBP-5074 in Healthy Subjects and Subjects With Renal ImpairmentCompletedPhase 1KBP BiosciencesNCT02653014Written as KBP-5074How we know
- Drug to Drug Interaction Study of KBP-5074 in Healthy SubjectsCompletedPhase 1KBP BiosciencesNCT04606537Written as KBP-5074How we know
- Pharmacokinetics of KBP-5074 in Patients With Moderate Hepatic ImpairmentCompletedPhase 1KBP BiosciencesNCT04534699Written as KBP-5074How we know
- Bioavailability of KBP-5074 Tablet vs Capsule FormulationsCompletedPhase 1KBP BiosciencesNCT03340753Written as KBP-5074 CapsuleHow we know
- Phase 1 Single Ascending Dose Study to Evaluate Safety, Tolerability and Pharmacokinetics of KBP-5074CompletedPhase 1KBP BiosciencesNCT02228733Written as KBP-5074How we know
What changed recently
From the registry's own updates since Oct 23, 2026.
Results posted1
Codes
What other systems call KBP-5074 · ClinicalTrials.gg INT001602
- MeSH (NLM) C000716354KBP-5074One source ClinicalTrials.gov
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000716354 | KBP-5074 | One source ClinicalTrials.gov |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.